Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients

BACKGROUND: Lactate dehydrogenase (LDH) represents a predictive factor in colorectal cancer patients treated with the angiogenesis inhibitor PTK/ZK. We explored the role of pre-treatment LDH serum levels in colorectal cancer patients receiving first-line bevacizumab. METHODS: Metastatic colorectal c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Scartozzi, M, Giampieri, R, Maccaroni, E, Del Prete, M, Faloppi, L, Bianconi, M, Galizia, E, Loretelli, C, Belvederesi, L, Bittoni, A, Cascinu, S
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2012
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3305976/
https://ncbi.nlm.nih.gov/pubmed/22315053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.17
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items